EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer

被引：57

作者：

de Mello, Ramon Andrade ^{[1
,2
,3
]}

Madureira, Pedro ^{[4
,5
]}

Carvalho, Liliana S. ^{[5
,6
]}

Araujo, Antonio ^{[1
,4
]}

O'Brien, Mary ^{[3
]}

Popat, Sanjay ^{[3
,7
]}

机构：

[1] Portuguese Oncol Inst, Dept Med Oncol, P-4200072 Oporto, Portugal

[2] Univ Porto FMUP, Fac Med, Dept Med, P-4200319 Oporto, Portugal

[3] Royal Marsden NHS Fdn Trust, Dept Med, London SW3 6JJ, England

[4] Univ Porto, ICBAS, P-4100 Oporto, Portugal

[5] IBMC, Oporto, Portugal

[6] Univ Porto, Fac Med, Dept Pharmacol & Therapeut, P-4200319 Oporto, Portugal

[7] Univ London Imperial Coll Sci Technol & Med, Mol Genet & Genom Grp, London, England

来源：

PHARMACOGENOMICS | 2013年 / 14卷 / 14期

关键词：

afatinib; ALK-EML4; bevacizumab; cetuximab; crizotinib; EGFR mutation; erlotinib; gefitinib; lung cancer; GROWTH-FACTOR-RECEPTOR; PHASE-III TRIAL; CISPLATIN-GEMCITABINE; ANTITUMOR-ACTIVITY; ERBB RECEPTORS; IMMUNOHISTOCHEMICAL EXPRESSION; MAINTENANCE THERAPY; GENE REARRANGEMENT; PROGNOSTIC-FACTORS; 1ST-LINE TREATMENT;

D O I：

10.2217/pgs.13.177

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Personalized therapy has significantly developed in lung cancer treatment over recent years. VEGF and EGF play a major role in non-small-cell lung cancer (NSCLC) tumor angiogenesis and aggressiveness. EGFR mutation as well as KRAS and ALK rearrangements are important biomarkers in the field owing to potential targeted therapies involved in clinical practice: erlotinib, geftinib, cetuximab and crizotinib. More recently, regulation of tumor immunity through CTLA4 and PD1/L1 has emerged as a promising field in NSCLC management. This review will focus on the current and future biomarkers in the advanced NSCLC field and also address potential related targeted therapies for these patients.

引用

页码：1765 / 1777

页数：13

共 130 条

[1]

Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer [J].

Adjei, Alex A. ;

Molina, Julian R. ;

Mandrekar, Sumithra J. ;

Marks, Randolph ;

Reid, Joel R. ;

Croghan, Gary ;

Hanson, Lorelei J. ;

Jett, James R. ;

Xia, Chenghua ;

Lathia, Chetan ;

Simantov, Ronit .

CLINICAL CANCER RESEARCH, 2007, 13 (09) :2684-2691

[2]

Novel therapeutic targets in non-small cell lung cancer [J].

Alamgeer, Muhammad ;

Ganju, Vinod ;

Watkins, D. Neil .

CURRENT OPINION IN PHARMACOLOGY, 2013, 13 (03) :394-401

[3]

Personalizing medicine - strategies for implementing the evaluation of ALK rearrangement in non-small-cell lung cancer in Portugal [J].

Araujo, A. ;

Coelho, A. ;

de Mello, R. ;

Azevedo, I. ;

Soares, M. ;

Queiroga, H. ;

Teixeira, E. ;

Parente, B. ;

Barata, F. .

REVISTA PORTUGUESA DE PNEUMOLOGIA, 2012, 18 (05) :244-246

[4]

K-ras mutations in non-small-cell lung carcinoma:: A review [J].

Aviel-Ronen, Sarit ;

Blackhall, Fiona H. ;

Shepherd, Frances A. ;

Tsao, Ming-Sound .

CLINICAL LUNG CANCER, 2006, 8 (01) :30-38

[5]

Epidermal growth factor receptor and KRAS mutations in Brazilian lung cancer patients [J].

Bacchi, Carlos E. ;

Ciol, Heloisa ;

Queiroga, Eduardo M. ;

Benine, Lucimara C. ;

Silva, Luciana H. ;

Ojopi, Elida B. .

CLINICS, 2012, 67 (05) :419-424

[6]

Novel anticancer targets: revisiting ERBB2 and discovering ERBB3 [J].

Baselga, Jose ;

Swain, Sandra M. .

NATURE REVIEWS CANCER, 2009, 9 (07) :463-475

[7]

Immunohistochemical Expression of Basic Fibroblast Growth Factor and Fibroblast Growth Factor Receptors 1 and 2 in the Pathogenesis of Lung Cancer [J].

Behrens, Carmen ;

Lin, Heather Y. ;

Lee, J. Jack ;

Raso, Maria Gabriela ;

Hong, Waun Ki ;

Wistuba, Ignacio I. ;

Lotan, Reuben .

CLINICAL CANCER RESEARCH, 2008, 14 (19) :6014-6022

[8]

Modes of resistance to anti-angiogenic therapy [J].

Bergers, Gabriele ;

Hanahan, Douglas .

NATURE REVIEWS CANCER, 2008, 8 (08) :592-603

[9]

The positive correlation between gene expression of the two angiogenic factors: VEGF and BMP-2 in lung cancer patients [J].

Bieniasz, Magdalena ;

Oszajca, Katarzyna ;

Eusebio, Mak ;

Kordiak, Jacek ;

Bartkowiak, Jacek ;

Szemraj, Janusz .

LUNG CANCER, 2009, 66 (03) :319-326

[10]

Phase II, Multicenter, Uncontrolled Trial of Single-Agent Sorafenib in Patients With Relapsed or Refractory, Advanced Non-Small-Cell Lung Cancer [J].

Blumenschein, George R., Jr. ;

Gatzemeier, Ulrich ;

Fossella, Frank ;

Stewart, David J. ;

Cupit, Lisa ;

Cihon, Frank ;

O'Leary, James ;

Reck, Martin .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (26) :4274-4280

← 1 2 3 4 5 6 7 8 9 10 →